Flurbiprofen
PubChem CID
3394
Structure
Primary Hazards
Molecular Formula
Synonyms
- flurbiprofen
- 5104-49-4
- Ansaid
- Froben
- Antadys
Molecular Weight
244.26 g/mol
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Dates
- Create:2005-03-25
- Modify:2026-04-04
Description
Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.
Flurbiprofen is a monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a monocarboxylic acid and a fluorobiphenyl. It is functionally related to a propionic acid. It derives from a hydride of a biphenyl.
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Chemical Structure Depiction
Interactive Chemical Structure Model
Conformer of 10
2-(3-fluoro-4-phenylphenyl)propanoic acid
Computed by Lexichem TK 2.9.3 (PubChem release 2025.09.15)
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
Computed by InChI 1.07.4 (PubChem release 2025.09.15)
SYTBZMRGLBWNTM-UHFFFAOYSA-N
Computed by InChI 1.07.4 (PubChem release 2025.09.15)
CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Computed by OEChem 4.2.0 (PubChem release 2025.09.15)
C15H13FO2
Computed by PubChem 2.2 (PubChem release 2025.09.15)
5104-49-4
51543-38-5
51543-38-5
FLURBIPROFEN
FLURBIPROFEN
MeSH Entry Terms for Flurbiprofen
- Flurbiprofen
- Flubiprofen
- Fluriproben
- 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic Acid
MeSH Entry Terms for Froben SR
Froben SR
MeSH Entry Terms for BTS-18322
BTS-18322
MeSH Entry Terms for Ansaid
Ansaid
MeSH Entry Terms for Cebutid
Cebutid
MeSH Entry Terms for Froben
Froben
MeSH Entry Terms for Strefen
Strefen
- flurbiprofen
- 5104-49-4
- Ansaid
- Froben
- Antadys
- 2-(3-fluoro-4-phenylphenyl)propanoic acid
- 2-(2-fluorobiphenyl-4-yl)propanoic acid
- Cebutid
- Flubiprofen
- Flurbiprofene
- Flurbiprofeno
- 3-Fluoro-4-phenylhydratropic acid
- Zepolas
- Flurbiprofenum
- BTS-18322
- U-27182
- BTS 18322
- (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
- 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
- 5GRO578KLP
- BTS 18,322
- NSC-757037
- CHEBI:5130
- DTXSID0037231
- U-27,182
- DTXCID8017231
- NSC685701
- Fluriproben
- (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+-)-
- Froben Sr
- Strefen
- Novo Flurprofen
- Nu Flurbiprofen
- Apo Flurbiprofen
- Rinol-STroche
- ratio Flurbiprofen
- RefChem:55218
- 2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid
- Antiphlamine Pain Relieving
- M01AE09
- M02AA19
- R02AX01
- S01BC04
- BTS18322
- (2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid
- 225-827-6
- Flurofen
- Ocufen
- Flurbiprofene [INN-French]
- Flurbiprofenum [INN-Latin]
- Flurbiprofeno [INN-Spanish]
- MFCD00079303
- FP 70
- Stayban
- 2-(2-FLUORO-[1,1'-BIPHENYL]-4-YL)PROPANOIC ACID
- 51543-38-5
- Adfeed
- U 27182
- 2-(2-Fluoro-4-biphenylyl)propionic acid
- (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
- CHEMBL563
- 2-Fluoro-alpha-methyl-4-biphenylacetic acid
- MLS000040873
- 2-(3-fluoro-4-phenyl-phenyl)propanoic acid
- Flugalin
- 2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid
- Anmetarin
- SMR000042823
- Yakuban
- 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid
- Ocuflur
- 2-(2-Fluorobiphenyl-4-yl)propionic Acid
- Flurbiprofen (Ansaid)
- Ansaid (TN)
- CCRIS 3708
- SR-01000003043
- FLP
- (R)-Flurbiprofen;MPC7869
- EINECS 225-827-6
- (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid
- UNII-5GRO578KLP
- U 27,182
- Flurbiprofen; (2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid
- Flurbiprofen O
- MKS-11
- rac-Flurbiprofen
- s1679
- Froben;
- Flurbiprofen CRS
- 2-(2-FLUORO-4-BIPHENYLYL)PROPANOIC ACID
- NCGC00016654-01
- (+-)Flurbiprofen
- CAS-5104-49-4
- EINECS 257-262-6
- Ocufen (Salt/Mix)
- [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-?-methyl-
- (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid
- Flurbiprofen (NSAID)
- Flurbiprofen [USAN:USP:INN:BAN:JAN]
- Spectrum_001096
- Flurbiprofen (Standard)
- Opera_ID_777
- Prestwick0_000917
- Prestwick1_000917
- Prestwick2_000917
- Prestwick3_000917
- Spectrum2_001025
- Spectrum3_000435
- Spectrum4_000558
- Spectrum5_000720
- FLURBIPROFEN [MI]
- F0371
- (.+/-.)-Flurbiprofen
- Flurbiprofendl-Flurbiprofen
- FLURBIPROFEN [INN]
- FLURBIPROFEN [JAN]
- Epitope ID:613431
- 4-Biphenylacetic acid, 2-fluoro-alpha-methyl-
- FLURBIPROFEN [USAN]
- SCHEMBL2248
- FLURBIPROFEN [VANDF]
- 4-Biphenylacetic acid, 2-fluoro-.alpha.-methyl-
- BSPBio_000794
- BSPBio_002050
- FLURBIPROFEN [MART.]
- KBioGR_001255
- KBioSS_001576
- MLS000028441
- MLS000758198
- MLS001201729
- MLS001401361
- MLS006011431
- MLS006011931
- DivK1c_000804
- FLURBIPROFEN [USP-RS]
- FLURBIPROFEN [WHO-DD]
- SPECTRUM1500308
- 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid
- SPBio_001209
- SPBio_002983
- BPBio1_000874
- GTPL4194
- orb1310752
- SCHEMBL10029029
- Flurbiprofen (JP18/USP/INN)
- HMS502I06
- KBio1_000804
- KBio2_001576
- KBio2_004144
- KBio2_006712
- KBio3_001270
- SYTBZMRGLBWNTM-UHFFFAOYSA-
- [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-
- MSK7164
- NINDS_000804
- FLURBIPROFEN [ORANGE BOOK]
- HMS1570H16
- HMS1920O20
- HMS2051A05
- HMS2090I06
- HMS2091F21
- HMS2097H16
- HMS2232I08
- HMS3259I12
- HMS3268E10
- HMS3370N14
- HMS3371I05
- HMS3393A05
- HMS3414N17
- HMS3649K11
- HMS3655G19
- HMS3678N15
- HMS3714H16
- HMS5079N10
- Pharmakon1600-01500308
- FLURBIPROFEN [EP MONOGRAPH]
- 2-FLUORO-[1,1'-BIPHENYL]-4-(ALPHA-METHYL)ACETIC ACID
- FLURBIPROFEN [USP MONOGRAPH]
- Tox21_110547
- Tox21_302353
- BBL010980
- BDBM50074922
- CCG-40243
- EBC-26294
- Flurbiprofen - CAS 5104-49-4
- HB3049
- HY-10582R
- MSK7164-100M
- NSC755404
- NSC757037
- SBB067242
- STK802101
- Flurbiprofen, cyclooxygenase inhibitor
- AKOS004119934
- AKOS016340701
- MSK7164-1000M
- AC-8106
- CCG-100759
- DB00712
- FF23507
- KS-5035
- NC00009
- NC00563
- NSC 757037
- NSC-685701
- NSC-755404
- 2(2-Fluoro-4-biphenylyl)propionic acid
- Flurbiprofen for peak identification CRS
- IDI1_000804
- NCGC00018157-03
- NCGC00018157-04
- NCGC00018157-05
- NCGC00018157-08
- NCGC00018157-11
- NCGC00018157-13
- NCGC00025287-03
- NCGC00025287-04
- NCGC00255457-01
- HY-10582
- NCI60_030812
- SY057091
- 2 -(2-fluoro-4-biphenylyl)propionic acid
- 2-(2-fluoro-4-biphenylyl)-propionic acid
- 2-(2-fluoro-biphenyl-4-yl)propionic acid
- SBI-0051387.P003
- DB-051888
- 2-(2-fluoro-biphenyl-4-yl)-propionic acid
- AB00051999
- Flurbiprofen Solution in Methanol, 100ug/mL
- NS00003058
- ST50825909
- alpha-methyl-2-fluoro-4-biphenylylacetic acid
- Flurbiprofen Solution in Methanol, 1000ug/mL
- (RS)-2-(2-fluorobiphenyl-4-yl)propionic acid
- 2-Fluoro-.alpha.-methyl-4-biphenylacetic acid
- BIM-0051387.0001
- C07013
- D00330
- AB00051999-17
- AB00051999_18
- EN300-7479231
- 2-fluoro--methyl-(1,1'-biphenyl)-4-acetic acid
- AO-295/42284050
- F463477
- Q419890
- (.+/-.)-2-(2-Fluoro-4-biphenylyl)propionic acid
- (r/s)-2-fluoro-alpha-methyl-4-biphenylacetic acid
- SR-01000003043-2
- SR-01000003043-5
- SR-01000003043-6
- 2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid
- 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid #
- BRD-A86044036-001-05-9
- BRD-A86044036-001-26-5
- BRD-A86044036-001-27-3
- SR-01000003043-14
- (+/-)-2-(2-FLUORO-4-BIPHENYLYL)PROPIONIC ACID
- (.+/-.)-2-Fluoro-.alpha.-methyl-4-biphenylacetic acid
- 2-Fluoro-.alpha.-methyl(1,1'-biphenyl)-4-acetic acid
- 2-fluoro-alpha-methyl-(1,1''-biphenyl)-4-acetic acid
- Z2216885233
- (+/-)-2-FLUORO-.ALPHA.-METHYL-4-BIPHENYLACETIC ACID
- [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (+/-)-
- Flurbiprofen, European Pharmacopoeia (EP) Reference Standard
- (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+/-)-
- [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (A+/-)-
- Flurbiprofen, United States Pharmacopeia (USP) Reference Standard
- [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-, (.+/-.)-
- 2-[2-Fluoro-[1,1 inverted exclamation mark -biphenyl]-4-yl]propanoic Acid
- (1,1'-BIPHENYL)-4-ACETIC ACID, 2-FLUORO-.ALPHA.-METHYL-, (+/-)-
- Flurbiprofen, 2-(2-Fluorobiphenyl-4-yl)propionic acid, 3-Fluoro-4-phenylhydratropic acid
- Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material
- InChI=1/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
Property Name
Property Value
Reference
Property Name
Molecular Weight
Property Value
244.26 g/mol
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
XLogP3
Property Value
4.2
Reference
Computed by XLogP3 3.0 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Donor Count
Property Value
1
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Acceptor Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Rotatable Bond Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Exact Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Monoisotopic Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Topological Polar Surface Area
Property Value
37.3 Ų
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Heavy Atom Count
Property Value
18
Reference
Computed by PubChem
Property Name
Formal Charge
Property Value
0
Reference
Computed by PubChem
Property Name
Complexity
Property Value
286
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Isotope Atom Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Atom Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Atom Stereocenter Count
Property Value
1
Reference
Computed by PubChem
Property Name
Defined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Covalently-Bonded Unit Count
Property Value
1
Reference
Computed by PubChem
Property Name
Compound Is Canonicalized
Property Value
Yes
Reference
Computed by PubChem (release 2025.09.15)
Solid
110-111 °C
Adams, S.S., Bernard, J., Nicholson, J.S. and Blancafort, A.R.; U.S. Patent 3,755,427; Aug. 28, 1973; assigned to The Boots Company Ltd.
110 - 111 °C
8 mg/L (at 22 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
2.49e-02 g/L
4.16
HANSCH,C ET AL. (1995)
3.8
-4.49
ADME Research, USCD
Acidic pKa
4.03
Acidic pKa
4.22
Acidic pKa
4.3
152.9 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
143.88 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
155.9 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Ross et al. JASMS 2022; 33; 1061-1072. DOI:10.1021/jasms.2c00111
Pharmaceuticals -> Analgesics and anti-inflammatories
S57 | GREEKPHARMA | Suspect Pharmaceuticals from the National Organization of Medicine, Greece | DOI:10.5281/zenodo.3248883
Pharmaceuticals -> Musculo-skeletal system -> Anti-inflammatory and antirheumatic products
S92 | FLUOROPHARMA | List of ~340 ATC classified fluoro-pharmaceuticals | DOI:10.5281/zenodo.5979646
Pharmaceuticals
S10 | SWISSPHARMA | Pharmaceutical List with Consumption Data | DOI:10.5281/zenodo.2623484
Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal
FDA approved drugs -> Active ingredient
Pharmaceuticals
S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
1D NMR Spectra
Spectra ID
Instrument Type
JEOL
Frequency
400 MHz
Solvent
CDCl3
Shifts [ppm]:Intensity
7.41:235.00, 7.13:222.00, 7.13:176.00, 3.75:71.00, 7.42:242.00, 7.44:100.00, 7.37:135.00, 7.36:102.00, 7.16:349.00, 7.54:167.00, 7.34:65.00, 7.40:72.00, 7.39:409.00, 7.53:320.00, 7.33:90.00, 7.40:64.00, 7.34:63.00, 7.33:47.00, 7.37:325.00, 3.80:65.00, 1.56:1000.00, 7.50:46.00, 7.45:182.00, 7.51:363.00, 7.51:390.00, 1.54:985.00, 7.53:235.00, 7.52:82.00, 3.77:211.00, 7.41:320.00, 7.37:290.00, 7.35:250.00, 7.18:192.00, 7.44:267.00, 7.16:209.00, 7.17:264.00, 7.42:536.00, 7.41:195.00, 3.78:205.00
Thumbnail
Source of Spectrum
Sigma-Aldrich Co. LLC.
Source of Sample
Sigma-Aldrich Co. LLC.
Catalog Number
447994
Copyright
Copyright © 2021-2025 Sigma-Aldrich Co. LLC. - Database Compilation Copyright © 2021-2025 John Wiley & Sons, Inc. All Rights Reserved.
Thumbnail
Spectra ID
Instrument Type
JEOL
Frequency
100.54 MHz
Solvent
CDCl3
Shifts [ppm]:Intensity
128.26:94.00, 128.46:1000.00, 44.89:271.00, 115.28:215.00, 140.90:139.00, 17.98:389.00, 115.52:193.00, 123.71:236.00, 130.91:234.00, 135.44:145.00, 158.48:87.00, 128.98:545.00, 160.96:101.00, 128.13:105.00, 140.98:139.00, 123.67:221.00, 127.72:424.00, 130.87:247.00, 180.43:167.00, 128.95:477.00
Thumbnail
Copyright
Copyright © 2016-2025 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved.
Thumbnail
NIST Number
248229
Library
Main library
Total Peaks
122
m/z Top Peak
199
m/z 2nd Highest
244
m/z 3rd Highest
178
Thumbnail
NIST Number
246396
Library
Replicate library
Total Peaks
77
m/z Top Peak
199
m/z 2nd Highest
244
m/z 3rd Highest
178
Thumbnail
Spectra ID
Instrument Type
LC-ESI-qTof
Ionization Mode
Positive
Top 5 Peaks
199.091858 17272
178.077255 4708
179.085587 4088
184.067764 2372
200.09436 2368
Thumbnail
Notes
From GNPS Library
Spectra ID
Instrument Type
LC-ESI-qTof
Ionization Mode
Positive
Top 5 Peaks
199.091919 11200
179.086121 3604
178.077332 2892
184.067947 2228
200.094727 1500
Thumbnail
Notes
From GNPS Library
Accession ID
Authors
Nihon Waters K.K.
Instrument
ZQ, Waters
Instrument Type
LC-ESI-Q
MS Level
MS
Ionization Mode
NEGATIVE
Ionization
ESI
Column Name
2.1 mm id - 3. 5{mu}m XTerra C18MS
Retention Time
18.000 min
Top 5 Peaks
199 999
177 404
101 384
151 313
197 243
Thumbnail
License
CC BY-NC
Accession ID
Authors
Nihon Waters K.K.
Instrument
ZQ, Waters
Instrument Type
LC-ESI-Q
MS Level
MS
Ionization Mode
NEGATIVE
Ionization
ESI
Column Name
2.1 mm id - 3. 5{mu}m XTerra C18MS
Retention Time
18.000 min
Top 5 Peaks
199 999
197 302
200 145
177 141
179 114
Thumbnail
License
CC BY-NC
Technique
Mull
Source of Spectrum
Sigma-Aldrich Co. LLC.
Source of Sample
Aldrich
Catalog Number
447994
Copyright
Copyright © 2018-2025 Sigma-Aldrich Co. LLC. - Database Compilation Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
Thumbnail
Instrument Name
Bio-Rad FTS
Technique
ATR-Neat (DuraSamplIR II)
Source of Spectrum
Forensic Spectral Research
Source of Sample
Alltech Associates, Inc., Grace Davison Discovery Sciences
Catalog Number
01674
Lot Number
519
Copyright
Copyright © 2009-2025 John Wiley & Sons, Inc. All Rights Reserved.
Thumbnail
Technique
FT-Raman
Source of Spectrum
Forensic Spectral Research
Source of Sample
Alltech Associates, Inc., Grace Davison Discovery Sciences
Catalog Number
01674
Lot Number
519
Copyright
Copyright © 2012-2025 John Wiley & Sons, Inc. All Rights Reserved.
Thumbnail
Follow these links to do a live 2D search or do a live 3D search for this compound, sorted by annotation score. This section is deprecated (see the neighbor discontinuation help page for details), but these live search links provide equivalent functionality to the table that was previously shown here.
Same Connectivity Count
Same Stereo Count
Same Isotope Count
Same Parent, Connectivity Count
Same Parent, Stereo Count
Same Parent, Isotope Count
Same Parent, Exact Count
Mixtures, Components, and Neutralized Forms Count
Similar Compounds (2D)
Similar Conformers (3D)
Oxaprozin (related)
Flurbiprofen Sodium (active moiety of)
Provider
Information
PubChem SID: 459217023
Purchasable Chemical: GID_900000004695792
PubChem SID: 459221487
Purchasable Chemical: GID_900000006471923
PubChem SID: 459221488
Purchasable Chemical: GID_900000006471924
PubChem SID: 463915510
Purchasable Chemical: RCLTRF598700
PubChem SID: 472870071
Purchasable Chemical: ACM1185133816
PubChem SID: 486388840
Purchasable Chemical: ACM51543385
PubChem SID: 488251606
Purchasable Chemical: 51543-38-5
PubChem SID: 474169216
Purchasable Chemical: EN300-7479231
PubChem SID: 475521183
Purchasable Chemical: Z2216885233
CATO Research Chemicals Inc. (Chemical Vendors, Research and Development)
PubChem SID: 513782410
Purchasable Chemical: CCAD301333
PubChem SID: 404848542
Purchasable Chemical: DRE-C13808000
PubChem SID: 521403312
Purchasable Chemical: EPF0285200
PubChem SID: 521405889
Purchasable Chemical: EPY0002271
PubChem SID: 470632519
Purchasable Chemical: CQ_5104-49-4
PubChem SID: 316898053
Purchasable Chemical: AC-8106
PubChem SID: 520685037
Purchasable Chemical: BB_SC-01257
PubChem SID: 464751256
Purchasable Chemical: starbld0585334
PubChem SID: 164788847
Purchasable Chemical: FT-0603668
PubChem SID: 164834057
Purchasable Chemical: FT-0660285
PubChem SID: 347897682
Purchasable Chemical: FT-0668760
PubChem SID: 496159048
Purchasable Chemical: 34255
PubChem SID: 329749901
Purchasable Chemical: 1285750_USP
PubChem SID: 329799649
Purchasable Chemical: F0285200_SIAL
PubChem SID: 24894968
Purchasable Chemical: F8514_SIGMA
PubChem SID: 506210111
Purchasable Chemical: CAS-5104-49-4
PubChem SID: 169618807
Purchasable Chemical: MCULE-4306860727
PubChem SID: 108667138
Purchasable Chemical: AKOS004119934
PubChem SID: 218903373
Purchasable Chemical: AKOS016340701
PubChem SID: 518804082
Purchasable Chemical: MSK7164-1000M
PubChem SID: 518804083
Purchasable Chemical: MSK7164-100M
PubChem SID: 521257426
Purchasable Chemical: API0233171
PubChem SID: 505919051
Purchasable Chemical: API5104494
PubChem SID: 88460285
Purchasable Chemical: MolPort-000-812-253
PubChem SID: 126921446
Purchasable Chemical: AO-295/42284050
PubChem SID: 383536463
Purchasable Chemical: BBS-00029367
PubChem SID: 384117162
Purchasable Chemical: STT-00466668
PubChem SID: 434378485
Purchasable Chemical: CSSB00000015096
PubChem SID: 522881730
Purchasable Chemical: RM-F210600
PubChem SID: 143439013
Purchasable Chemical: SBB067242
PubChem SID: 143858105
Purchasable Chemical: ST50825909
PubChem SID: 313075605
Purchasable Chemical: CS-O-01530
PubChem SID: 381024583
Purchasable Chemical: VL279936-1G
PubChem SID: 485171263
Purchasable Chemical: evt-7894404
PubChem SID: 516434128
Purchasable Chemical: orb1310752
MeSH Heading
EFO Term
Max Phase
Page of 4
Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
Flurbiprofen is a nonsteroidal antiinflammatory drug (NSAID) used in treatment of mild-to-moderate pain and symptoms of chronic arthritis. Flurbiprofen has been linked to a low rate of serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver injury.
Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal
Nonsteroidal Antiinflammatory Drugs
Drug
Active Ingredient
Form;Route
Company
Date
Drug
Active Ingredient
Flurbiprofen
Form;Route
TABLET;ORAL
Company
PHARMACIA AND UPJOHN
Date
5/9/2016
Drug
Ingredient(s)
Dosage Form/Route
Strength
Marketing Status
Company
Application Number
Production Number
Drug
Ingredient(s)
FLURBIPROFEN
Dosage Form/Route
TABLET;ORAL
Strength
50MG
Marketing Status
Discontinued
Company
PHARMACIA AND UPJOHN
Application Number
Production Number
002
Drug
Ingredient(s)
FLURBIPROFEN
Dosage Form/Route
TABLET;ORAL
Strength
100MG
Marketing Status
Discontinued
Company
PHARMACIA AND UPJOHN
Application Number
Production Number
003
Drug
Ingredient(s)
FLURBIPROFEN
Dosage Form/Route
TABLET;ORAL
Strength
50MG
Marketing Status
Discontinued
Company
NATCO PHARMA
Application Number
Production Number
001
Drug
Ingredient(s)
FLURBIPROFEN
Dosage Form/Route
TABLET;ORAL
Strength
100MG
Marketing Status
Discontinued
Company
NATCO PHARMA
Application Number
Production Number
002
Drug
Ingredient(s)
FLURBIPROFEN
Dosage Form/Route
TABLET;ORAL
Strength
100MG
Marketing Status
Discontinued
Company
TEVA
Application Number
Production Number
001
Page of 4
Trade Name
Application Number
Product Number
Applicant
Approval Date
Trade Name
Application Number
Product Number
002
Applicant
PHARMACIA AND UPJOHN CO
Approval Date
Oct 31, 1988
Trade Name
Application Number
Product Number
003
Applicant
PHARMACIA AND UPJOHN CO
Approval Date
Oct 31, 1988
Trade Name
Application Number
Product Number
001
Applicant
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
Approval Date
May 31, 1995
Trade Name
Application Number
Product Number
002
Applicant
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
Approval Date
May 31, 1995
Trade Name
Application Number
Product Number
001
Applicant
NEW HEIGHTSRX LLC
Approval Date
May 31, 1995
Page of 4
Product NDC
Start Marketing Date
Dosage Form
Strength
Labeler
Product NDC
Start Marketing Date
1995-06-02
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Bryant Ranch Prepack
Product NDC
Start Marketing Date
1995-06-02
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Bryant Ranch Prepack
Product NDC
Start Marketing Date
2024-11-01
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Genus Lifesciences
Product NDC
Start Marketing Date
1995-06-02
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
NuCare Pharmaceuticals,Inc.
Product NDC
Start Marketing Date
2025-08-01
Dosage Form
TABLET
Strength
100 mg/1
Labeler
IPG Pharmaceuticals, Inc.
Page of 2
Drug and label
- Ingredient (UNII): FLURBIPROFEN (UNII:5GRO578KLP)Indication: Indications & Usage: For the temporary relief of Shoulder Pain, Backache, Neuralgia, Arthralgia, Sore Muscles, Sprains, Bruises, Rheumatic Pain, and Fracture Pain.Category: Human over the counterCompany: HANUL TRADING CO., LTD.Date: 2015-10-13
- Ingredient (UNII): FLURBIPROFEN (UNII:5GRO578KLP)Indication: please see attached Drug FactsCategory: Human over the counterCompany: Lydia Co., Ltd.Date: 2024-10-31
- Ingredient (UNII): FLURBIPROFEN (UNII:5GRO578KLP)Description: Flurbiprofen tablet, USP contain flurbiprofen, which is a member of the phenylalkanoic acid derivative group of nonsteroidal anti-inflammatory drugs. Flurbiprofen tablet, USP are white, oval, film-coated tablets for oral...Indication: Carefully consider the potential benefits and risks of Flurbiprofen tablet, USP and other treatment options before deciding to use Flurbiprofen tablet, USP. Use the lowest effective dose for the shortest duration consistent...Category: Human prescriptionCompany: CARACO PHARMACEUTICAL LABORATORIES, LTD.Date: 2007-08-09
- Ingredient (UNII): FLURBIPROFEN (UNII:5GRO578KLP)Description: DESCRIPTIONFlurbiprofen is a member of the phenylalkanoic acid derivative group of non-steroidal anti-inflammatory drugs. Flurbiprofen tablets are beige, round, film-coated tablets for oral administration. Flurbiprofen is a...Indication: INDICATIONS AND USAGECarefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets. Use the lowest effective dose for the shortest...Category: Human prescriptionCompany: STAT RX USA LLCDate: 2009-05-15
- Ingredient (UNII): FLURBIPROFEN (UNII:5GRO578KLP)Category: Human prescriptionCompany: Physicians Total Care, Inc.Date: 2012-06-12
Page of 3
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult ParticipantsCTID: NCT07223671Phase: Phase 1Status: CompletedDate: 2026-03-27
- Efficacy of Flurbiprofen Spray for Postoperative Sore Throat Following Double-Lumen Endobronchial IntubationCTID: NCT07163429Phase: N/AStatus: Active, not recruitingDate: 2026-03-24
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsCTID: NCT07235748Phase: Phase 1Status: CompletedDate: 2026-02-17
- To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy SubjectsCTID: NCT06823284Phase: Phase 1Status: CompletedDate: 2025-03-11
- Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract InfectionsCTID: NCT05955885Phase: Early Phase 1Status: CompletedDate: 2024-12-06
Page of 8
- Randomized, controlled, multi-center trial to evaluate the efficacy and safety of a Flurbiprofen 40 mg cutaneous hydrogel medicated plaster vs. placebo and vs. a marketed active comparator in the local symptomatic and short-term treatment of pain in acute strains, sprains or bruises of the soft tissues following blunt trauma, e.g. sports injuriesEudraCT: 2020-005217-41Phase: Phase 3Status: CompletedDate: 2021-09-06
- Randomized, controlled, double-blind, multi-center trial to evaluate theEudraCT: 2020-005165-14Phase: Phase 2Status: CompletedDate: 2021-03-25
- SUBGLOTTIC INSTILLATION OF FLURBIPROFENE TO PREVENT LARYNGEAL INFLAMMATION FOLLOWING ENDOTRACHEAL INTUBATION: PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PILOT STUDYEudraCT: 2020-000886-17Phase: Phase 2Status: CompletedDate: 2020-11-02
- TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trialEudraCT: 2014-004483-38Phase: Phase 2Status: CompletedDate: 2015-07-16
- Analgesic profile of 3 new Ibuprofen lozenges (V0498TA01A 15mg, 25mg,EudraCT: 2011-005848-10Phase: Phase 2Status: CompletedDate: 2012-02-06
Page of 3
- Changes of thromboxane B2 following to lung collapse during thoracotomyCTID: UMIN000034950Status: Complete: follow-up completeDate: 2018-11-20
- Comparison of the analgesic effect of intravenous acetaminophen with that of flurbiprofen axetil after lumbar disc surgeryCTID: UMIN000032207Phase: Not applicableStatus: RecruitingDate: 2018-04-16
- Comparison of the effect on the postoperative pain between intravenous acetaminophen and flurbiprofen after total knee arthroplasty: a randomized controlled trialCTID: UMIN000029487Status: Complete: follow-up completeDate: 2017-10-10
- The research to take the oral tablet morphine sulphate for preoperative under general anesthesia: to postoprative pain and sedationCTID: UMIN000028193Status: Complete: follow-up completeDate: 2017-07-12
- The examination of concentration of drug in tissues from the knee osteoarthritis patients who use the Esflurbiprofen tape or FlurbiprofenCTID: UMIN000024789Status: Complete: follow-up completeDate: 2016-11-10
Page of 3
- Category/Dataset: EMA Article 57Product/no.: Strepfen Orange Sugar FreeActive Substance: FlurbiprofenStatus: Product authorisation country: GreeceAdministration Route: Oromucosal Use
- Category/Dataset: EMA Article 57Product/no.: Apifen Mel E Limão Sem AçúcarActive Substance: FlurbiprofenStatus: Product authorisation country: PortugalAdministration Route: Oral Use ,Oromucosal Use
- Category/Dataset: EMA Article 57Product/no.: Flurbiprofen GalenikaActive Substance: FlurbiprofenStatus: Product authorisation country: Czech RepublicAdministration Route: Oral Use
- Category/Dataset: EMA Article 57Product/no.: FlurbiprofenActive Substance: FlurbiprofenStatus: Product authorisation country: Croatia; SloveniaAdministration Route: Oral Use ,Oromucosal Use
- Category/Dataset: EMA Article 57Product/no.: Oroflurb NeoActive Substance: FlurbiprofenStatus: Product authorisation country: SlovakiaAdministration Route: Oropharyngeal Use
Page of 57
Max Phase
Approved
First Approval
1986
Black Box Warning
Yes
Availability Type
Prescription Only
Route of Administration
Oral; Topical
Warning Type
Warning Class
Country
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Cyclooxygenase inhibitor
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Cyclooxygenase inhibitor
Compound CID: 338Interaction: The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylic acid.
Page of 330
- Avoid alcohol.
- Take with food. Food reduces irritation.
Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
FDA UNII
5GRO578KLP
Active Moiety
FLURBIPROFEN
Pharmacological Classes
Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors
Pharmacological Classes
Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal
Pharmacological Classes
Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug
FDA Pharmacology Summary
Flurbiprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of flurbiprofen is as a Cyclooxygenase Inhibitor.
Non-Proprietary Name
FLURBIPROFEN
Pharmacological Classes
Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]
Non-Proprietary Name
FLUBIPROFEN
Pharmacological Classes
Cyclooxygenase Inhibitors [MoA]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Nonsteroidal Anti-inflammatory Drug [EPC]
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01B - Antiinflammatory agents
S01BC - Antiinflammatory agents, non-steroids
S01BC04 - Flurbiprofen
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01A - Antiinflammatory and antirheumatic products, non-steroids
M01AE - Propionic acid derivatives
M01AE09 - Flurbiprofen
M - Musculo-skeletal system
M02 - Topical products for joint and muscular pain
M02A - Topical products for joint and muscular pain
M02AA - Antiinflammatory preparations, non-steroids for topical use
M02AA19 - Flurbiprofen
R - Respiratory system
R02 - Throat preparations
R02A - Throat preparations
R02AX - Other throat preparations
R02AX01 - Flurbiprofen
ATCvet Code
QM - Musculo-skeletal system
QM01 - Antiinflammatory and antirheumatic products
QM01A - Antiinflammatory and antirheumatic products, non-steroids
QM01AE - Propionic acid derivatives
QM01AE09 - Flurbiprofen
ATCvet Code
QS - Sensory organs
QS01 - Ophthalmologicals
QS01B - Antiinflammatory agents
QS01BC - Antiinflammatory agents, non-steroids
QS01BC04 - Flurbiprofen
ATCvet Code
QR - Respiratory system
QR02 - Throat preparations
QR02A - Throat preparations
QR02AX - Other throat preparations
QR02AX01 - Flurbiprofen
ATCvet Code
Absorption
Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration.
Route of Elimination
Flurbiprofen is poorly excreted into human milk. Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Renal elimination is a significant pathway of elimination of flurbiprofen metabolites.
Volume of Distribution
14 L [Normal Healthy Adults]
12 L [Geriatric Arthritis Patients]
10 L [End Stage Renal Disease Patients]
14 L [Alcoholic Cirrhosis Patients]
0.12 L/kg
> 99% bound, primarily to albumin. Binds to a different primary binding site on albumin than anticoagulants, sulfonamides and phenytoin.
Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.
Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.
Route of Elimination: Flurbiprofen is poorly excreted into human milk. Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Renal elimination is a significant pathway of elimination of flurbiprofen metabolites.
Half Life: R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours
R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours
Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.
- Cytoplasm
- Extracellular
- Membrane
Use (kg; approx.) in Germany (2009): >250
Consumption (g per capita; approx.) in Germany (2009): 0.00305
Calculated removal (%): 73.9
Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
Pharmaceuticals
S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
Pictogram(s)
Signal
Danger
GHS Hazard Statements
H301 (98.2%): Toxic if swallowed [Danger Acute toxicity, oral]
H315 (54.4%): Causes skin irritation [Warning Skin corrosion/irritation]
H319 (56.1%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H335 (57%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
Precautionary Statement Codes
ECHA C&L Notifications Summary
Aggregated GHS information provided per 114 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Acute Tox. 3 (98.2%)
Skin Irrit. 2 (54.4%)
Eye Irrit. 2 (56.1%)
STOT SE 3 (57%)
Repr. 2 (50%)
California Safe Cosmetics Program (CSCP) Reportable Ingredient
Hazard Traits - Developmental Toxicity; Reproductive Toxicity
Authoritative List - Prop 65
Report - regardless of intended function of ingredient in the product
Chemical Assessment
IMAP assessments - [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-: Environment tier I assessment
IMAP assessments - [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-: Human health tier I assessment
Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.
Prospective studies show that mild elevations in serum aminotransferase levels can occur in up to 15% of patients taking NSAIDs such as flurbiprofen, but the abnormalities are generally transient, mild and asymptomatic, often resolving even with drug continuation. Marked aminotransferase elevations above 3 times the upper limit of normal (ULN) occur in less than 1% of patients. Clinically apparent liver injury with jaundice from flurbiprofen is rare and only individual case descriptions have been published. The latency to onset is within 1 to 4 weeks of starting. The pattern of enzyme elevations is typically cholestatic, but hepatocellular cases have been described. Immunoallergic features are present in some cases (low grade fever, rash), but are generally not prominent, and autoantibody formation is rare. Most cases resolve promptly on stopping therapy. Flurbiprofen is not mentioned in large case series on drug induced liver injury or acute liver failure from the United States, but was listed as the second most common agent implicated in drug-induced liver injury in a case series from Turkey, one of which was fatal.
Likelihood score: C (probable rare cause of clinically apparent liver injury).
Dataset
Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)
Compound
flurbiprofen
Brand name
Ocufen®
Therapeutic category
NSAIDs
DILI severity Score
3
DILI concern
less-DILI-concern drugs
Status/label
Warnings and Precautions
Reference
Carcinogen Classification
No indication of carcinogenicity to humans (not listed by IARC).
◉ Summary of Use during Lactation
Because of the low levels of flurbiprofen in breastmilk and its short half-life it is unlikely to adversely affect the breastfed infant, especially if the infant is older than 2 months.
Maternal use of flurbiprofen eye drops would not be expected to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
◉ Effects in Breastfed Infants
A retrospective medical record review in Taiwan compared the full-term breastfed infants of women who received acetaminophen (n = 348) to those who received flurbiprofen (n = 132) for postpartum analgesia after a vaginal birth. There was no statistically significant difference in the percentage of infants with hyperbilirubinemia between those whose mothers received flurbiprofen (0.76%) and those whose mothers received acetaminophen(2.01%).
A study of full-term, vaginally delivered breastfed neonates compared those whose mothers received acetaminophen (n = 348) to those whose mothers received flurbiprofen (n = 132) for postpartum pain. Seven (2%) newborns of acetaminophen users had hyperbilirubinemia and 1 (0.76%) newborn of the flurbiprofen users had hyperbilirubinemia. The differences was not statistically significant.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration.
Symptoms of a flurbiprofen overdose may include nausea, vomiting, stomach pain, dizziness, drowsiness, black or bloody stools, coughing up blood, urinating less than usual or not at all, shallow breathing, fainting, or coma.
Compound CID
Organism
Test Type
Route
Dose
Effect
Reference
Compound CID
Organism
rat
Test Type
LD50
Route
oral
Dose
117 mg/kg
Effect
BEHAVIORAL: ATAXIA; GASTROINTESTINAL: HYPERMOTILITY, DIARRHEA; BLOOD: NORMOCYTIC ANEMIA
Reference
Kiso to Rinsho. Clinical Report., 9(2641), 1975
Compound CID
Organism
mouse
Test Type
LD50
Route
intraperitoneal
Dose
890 mg/kg
Effect
Reference
Russian Pharmacology and Toxicology, 49(98), 1986
Compound CID
Organism
rabbit
Test Type
LD50
Route
oral
Dose
290 mg/kg
Effect
Reference
Drugs in Japan, 6(707), 1982
Compound CID
Organism
women
Test Type
TDLo
Route
oral
Dose
14 mg/kg/7D-I
Effect
SKIN AND APPENDAGES (SKIN): DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE
Reference
Annals of Internal Medicine., 112(550), 1990
Compound CID
Organism
mouse
Test Type
LD50
Route
oral
Dose
640 mg/kg
Effect
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY); GASTROINTESTINAL: HYPERMOTILITY, DIARRHEA; BLOOD: NORMOCYTIC ANEMIA
Reference
Kiso to Rinsho. Clinical Report., 9(2641), 1975
Page of 3
LD50: 10 mg/kg (Oral, Dog) (A308)
Patients should be managed by symptomatic and supportive care following overdose with a nonsteroidal anti-inflammatory drug. There are no specific antidotes. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms, or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding. (L1712)
Source Disease
Data Source
Page of 4
- Publication Name: BMC AnesthesiologyPublication Date: 2025-07-29
- Publication Name: Reactions WeeklyPublication Date: 2025-07-26
- Publication Name: 3 BiotechPublication Date: 2025-07-25
- Publication Name: Journal of Clinical Monitoring and ComputingPublication Date: 2025-07-24PMID: 40702392
- Publication Name: Journal of Pharmaceutical InnovationPublication Date: 2025-07-24
Page of 1,220
- Publication Date: 2023Publication Name: Bioprospecting of Tropical Medicinal Plants
- PMID: 39945815Publication Date: 2025Publication Name: Naunyn-Schmiedeberg's Archives of Pharmacology
- Publication Date: 2024Publication Name: Structural Chemistry
Page of 780
- Publication Date: 2021Publication Name: Synthesis
- Publication Date: 2021Publication Name: Synfacts
- Publication Date: 2020Publication Name: Science of Synthesis
- Publication Date: 2019Publication Name: Synfacts
Page of 2
- Publication Date: 2025Publication Name: Science of Synthesis
- Publication Date: 2025Publication Name: Science of Synthesis
Page of 2
Chemical
Selected evidence
Chemical
Selected evidence
2,073 articles
View All- Flurbiprofen and its attenuating effect on intracranial ischemic injury as well as ischemia in other systemic organsPMID 23422124; Chinese medical journal 2013-02-01
- Excited state interactions between flurbiprofen and tryptophan in drug–protein complexes and in model dyads. Fluorescence studies from the femtosecond to the nanosecond time domainsPMID 23426282; DOI 10.1039/c3cp43847c; Physical chemistry chemical physics : PCCP 2013-04-07
- A Novel Oromucosal Prolonged Release Mucoadhesive Suspension by One Step Spray Coagulation MethodPMID 23432365; DOI 10.2174/1567201811310030001; Current Drug Delivery 2013-05-01
Chemical
Selected evidence
1,558 articles
View All- The effect of flurbiprofen oral spray and ibuprofen vs ibuprofen alone on postoperative tonsillectomy pain: An open, randomised, controlled trialPMID 29288561; DOI 10.1111/coa.13058; Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2018-01-18
- Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes.PMID 1981722; DOI 10.1016/s0090-9556(25)08633-7; Drug metabolism and disposition: the biological fate of chemicals 1990-09-01
- Direct distinction of ibuprofen and flurbiprofen enantiomers by ion mobility mass spectrometry of their ternary complexes with metal cations and cyclodextrins in the gas phasePMID 33823081; DOI 10.1002/jssc.202100025; Journal of Separation Science 2021-05-26
Chemical
Selected evidence
410 articles
View All- [Inhibitory effect of 2-(2-fluoro-4-biphenylyl)propionic acid (Flurbiprofen) on prostaglandin synthesis]PMID 1035562; DOI 10.1254/fpj.72.1025; Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1976-11-01
- Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-beta-cyclodextrinPMID 4032267; DOI 10.1002/jps.2600740808; Journal of Pharmaceutical Sciences 1985-08-01
- Treatment of rheumatoid arthritis with flurbiprofen: a comparison with enteric-coated aspirinPMID 7021070; DOI 10.1185/03007998109114278; Current Medical Research and Opinion 1981-01-01
Gene/Protein/Enzyme
Selected evidence
Gene/Protein/Enzyme
Selected evidence
63 articles
View All- Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cellsPMID 11059772; Cancer research 2000-10-15
- Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxibPMID 17431104; DOI 10.1158/1535-7163.mct-06-0629; Molecular Cancer Therapeutics 2007-04-01
- Up-regulation of cyclooxygenase-2 by product-prostaglandin E2PMID 9321948; DOI 10.1007/978-1-4899-1813-0_25; Advances in experimental medicine and biology 1997-01-01
Gene/Protein/Enzyme
Selected evidence
45 articles
View All- Alternative Splicing of Cyclooxygenase-1 mRNA in the Human IrisPMID 12711844; DOI 10.1159/000070052; Ophthalmic Research 2003-05-01
- Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cellsPMID 11059772; Cancer research 2000-10-15
- The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1PMID 8121489; DOI 10.1038/367243a0; Nature 1994-01-20
Gene/Protein/Enzyme
Selected evidence
31 articles
View All- Prediction of Metabolism by Cytochrome P450 2C9: Alignment and Docking Studies of a Validated Database of SubstratesPMID 18237107; DOI 10.1021/jm7009793; Journal of Medicinal Chemistry 2008-02-01
- Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypesPMID 12698304; DOI 10.1007/s00228-003-0574-6; European Journal of Clinical Pharmacology 2003-02-26
- CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysisPMID 17446262; DOI 10.1124/dmd.107.014910; Drug metabolism and disposition: the biological fate of chemicals 2007-07-01
Disease
Selected evidence
Disease
Selected evidence
16 articles
View All- Effect of Flurbiprofen and S-Flurbiprofen Patches on Multimodal Pain Management After Total Knee Arthroplasty: A Prospective Randomized Controlled TrialPMID 32362479; DOI 10.1016/j.arth.2020.04.006; The Journal of Arthroplasty 2020-08-01
- [Application of flurbiprofen axetil in pain management associated during transrectal ultrasound-guided prostate biopsy]PMID 28816281; Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2017-08-18
- Pain control during fixed orthodontic appliance therapyPMID 15825785; DOI 10.1043/0003-3219(2005)075<0210:pcdfoa>2.0.co;2; The Angle orthodontist 2005-03-01
Disease
Selected evidence
17 articles
View All- Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throatPMID 27146963; DOI 10.1080/03007995.2016.1187119; Current Medical Research and Opinion 2016-05-18
- The effects of S- and R-flurbiprofen on the inflammation-evoked intraspinal release of immunoreactive substance P--a study with antibody microprobesPMID 9666149; DOI 10.1016/s0006-8993(98)00429-6; Brain Research 1998-07-06
- The Use of an Artificial Skin Model to Study Transdermal Absorption of Drugs in Inflamed SkinPMID 22293350; DOI 10.1248/bpb.35.203; Biological and Pharmaceutical Bulletin 2012-01-01
Disease
Selected evidence
7 articles
View All- Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug, flurbiprofenPMID 3502173; Ophthalmic surgery 1987-12-01
- Comparison of the anti‐inflammatory effects of diclofenac and flurbiprofen eye drops after cataract extractionPMID 9686850; DOI 10.1034/j.1600-0420.1998.760318.x; Acta Ophthalmologica Scandinavica 1998-06-01
- The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatationPMID 11040914; DOI 10.1038/eye.2000.157; Eye (London, England) 2000-07-01
Organism
Selected evidence
Organism
Selected evidence
153 articles
View All- Up-regulation of cyclooxygenase-2 by product-prostaglandin E2PMID 9321948; DOI 10.1007/978-1-4899-1813-0_25; Advances in experimental medicine and biology 1997-01-01
- Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical studyPMID 23686785; DOI 10.1007/s13277-013-0836-6; Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013-05-18
- Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidinePMID 11372587; DOI 10.1007/s002280100268; European Journal of Clinical Pharmacology 2001-03-21
Organism
Selected evidence
37 articles
View All- Influence of Skin Thickness on the in Vitro Permeabilities of Drugs through Sprague-Dawley Rat or Yucatan Micropig SkinPMID 22293349; DOI 10.1248/bpb.35.192; Biological and Pharmaceutical Bulletin 2012-01-01
- Urethane anaesthesia could partly mask antinociceptive effects of non-steroidal anti-inflammatory drugs: a spinal c-Fos protein studyPMID 11164833; DOI 10.1016/s0006-8993(00)03254-6; Brain Research 2001-02-09
- SPECIAL REPORT: Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro‐derivative, nitroflurbiprofenPMID 8528547; DOI 10.1111/j.1476-5381.1995.tb16650.x; British Journal of Pharmacology 1995-09-01
Organism
Selected evidence
21 articles
View All- Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant‐induced arthritic ratsPMID 12692887; DOI 10.1002/chir.10227; Chirality 2003-05-15
- A Sensitive UPLC-MS/MS Method for the Determination of Flurbiprofen in Rat Plasma: Application to Real SamplePMID 33884406; DOI 10.1093/chromsci/bmab047; Journal of Chromatographic Science 2021-04-22
- Aortic hyporeactivity to norepinephrine induced by lipopolysaccharide in cirrhotic rats: Beneficial effects of a non‐steroidal anti‐inflammatory drug coupled with a nitric oxide donorPMID 11206319; DOI 10.1046/j.1440-1746.2001.02386.x; Journal of Gastroenterology and Hepatology 2001-01-01
- Publication Number: CN-120741734-APriority Date: 2025-06-30
- Publication Number: CN-120483870-APriority Date: 2025-05-07
- Publication Number: CN-120284921-APriority Date: 2025-05-06
- Publication Number: CN-120037177-APriority Date: 2025-04-10
- Publication Number: CN-120040394-APriority Date: 2025-04-02
Page of 20,613
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=SYTBZMRGLBWNTM-UHFFFAOYSA-N
Chemical
Selected evidence
Chemical
Selected evidence
3,632 patents from 2,343 patent families
View Top 1000- Process for preparing arylalkanoic acid derivativesUS-4107439-A; Grant Date: 1978-08-15
- Method of increasing coronary blood flow with ibuprofenUS-4282252-A; Grant Date: 1981-08-04
- Methods of increasing coronary blood flow through vasodilation by flurbiprofenUS-4337273-A; Grant Date: 1982-06-29
Chemical
Selected evidence
3,024 patents from 1,976 patent families
View Top 1000- Anti-inflammatory and analgesic gel compositionUS-4393076-A; Grant Date: 1983-07-12
- Enantioselective production of chiral carboxylic acidsUS-5273895-A; Grant Date: 1993-12-28
- Medicament containing a 2-arylpropionic acid derivative in nanosol form and its preparationUS-5560924-A; Grant Date: 1996-10-01
Chemical
Selected evidence
3,011 patents from 1,932 patent families
View Top 1000- Process for preparing arylalkanoic acid derivativesUS-4107439-A; Grant Date: 1978-08-15
- Enantioselective production of chiral carboxylic acidsUS-5273895-A; Grant Date: 1993-12-28
- Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatabilityUS-9968552-B2; Grant Date: 2018-05-15
Disease
Selected evidence
Disease
Selected evidence
2,016 patents from 1,342 patent families
View Top 1000- Therapeutic agentUS-4501727-A; Grant Date: 1985-02-26
- Therapeutic agentsUS-4786495-A; Grant Date: 1988-11-22
- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
Disease
Selected evidence
1,197 patents from 763 patent families
View Top 1000- Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animalsEP-0607128-B2; Grant Date: 2007-02-21
- Ophthalmic compositionUS-6265444-B1; Grant Date: 2001-07-24
- Treatment of migraine headacheUS-7030162-B2; Grant Date: 2006-04-18
Disease
Selected evidence
945 patents from 588 patent families
View All- External patchJP-4774179-B2; Grant Date: 2011-09-14
- PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDsEP-1411900-B2; Grant Date: 2013-12-04
- Combination therapy for rheumatoid arthritisUS-4355029-A; Grant Date: 1982-10-19
Gene
Selected evidence
Gene
Selected evidence
921 patents from 570 patent families
View All- Composition for use in transdermal administrationEP-0572494-B1; Grant Date: 1999-08-25
- Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing sameUS-5166331-A; Grant Date: 1992-11-24
- A mixture for transdermal delivery of low and high molecular weight compoundsEP-1684681-B1; Grant Date: 2018-10-24
Gene
Selected evidence
399 patents from 263 patent families
View All- Pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitorUS-6248745-B1; Grant Date: 2001-06-19
- Combination therapy of lower urinary tract dysfunction using α2δ ligand and NSAIDJP-5308350-B2; Grant Date: 2013-10-09
- Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptideUS-10329343-B2; Grant Date: 2019-06-25
Gene
Selected evidence
635 patents from 421 patent families
View All- Combinations of tumor necrosis factors and anti-inflammatory agents for treating malignant and non-malignant diseasesEP-0287633-B1; Grant Date: 1993-07-07
- Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseasesUS-4980160-A; Grant Date: 1990-12-25
- Composition comprising trehalose and zinc and use thereof to inhibit skin irritationEP-1499325-B1; Grant Date: 2008-07-16
Organism
Selected evidence
Organism
Selected evidence
2,454 patents from 1,607 patent families
View Top 1000- Anti-inflammatory and analgesic gel compositionUS-4393076-A; Grant Date: 1983-07-12
- Therapeutic agentsUS-4786495-A; Grant Date: 1988-11-22
- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
Organism
Selected evidence
1,576 patents from 1,028 patent families
View Top 1000- Analgesic mixture of nalbuphine and flurbiprofenUS-4404211-A; Grant Date: 1983-09-13
- Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactantUS-5110493-A; Grant Date: 1992-05-05
- Inflammation-preventing pharmaceutical composition of oral administrationUS-4421747-A; Grant Date: 1983-12-20
Organism
Selected evidence
1,033 patents from 697 patent families
View Top 1000- Method of increasing coronary blood flow with ibuprofenUS-4282252-A; Grant Date: 1981-08-04
- Methods of increasing coronary blood flow through vasodilation by flurbiprofenUS-4337273-A; Grant Date: 1982-06-29
- Anti-inflammatory and analgesic gel compositionUS-4393076-A; Grant Date: 1983-07-12
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Inhibition
Evidence
Data Source
Page of 10
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Inhibition
Evidence
Data Source
Page of 10
- Data Source: PathBankExternal ID: SMP0000697Taxonomy Name: Homo sapiens (human)
Page of 671
Page of 2
- A derivative of propionic acid, and a phenylalkanoic acid derivative of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure.
- A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
- Australian Industrial Chemicals Introduction Scheme (AICIS)[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-https://services.industrialchemicals.gov.au/search-assessments/
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusFlurbiprofen [USAN:USP:INN:BAN:JAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0005104494ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/chemidplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useFlurbiprofenhttps://www.drugbank.ca/drugs/DB00712
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxFlurbiprofenhttps://comptox.epa.gov/dashboard/DTXSID0037231CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeFlurbiprofenhttps://chem.echa.europa.eu/100.023.479(±)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acidhttps://chem.echa.europa.eu/100.052.039Flurbiprofen (EC: 225-827-6)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/30385
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.https://www.hmdb.ca/citingFlurbiprofenhttp://www.hmdb.ca/metabolites/HMDB0014850HMDB0014850_msms_374464https://hmdb.ca/metabolites/HMDB0014850#spectra
- NIAID ChemDBLICENSEThe NIAID ChemDB information received cannot be sold and is only to be used for research purposes.2-(3-fluoro-4-phenyl-phenyl)propanoic acidhttps://pubchem.ncbi.nlm.nih.gov/substance/?source=niaid&sourceid=335510
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acidhttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50074922
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsFLURBIPROFENhttps://www.dgidb.org/drugs/rxcui:4502
- DrugCentralflurbiprofenhttps://drugcentral.org/drugcard/1219
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)Flurbiprofenhttps://ttd.idrblab.cn/data/drug/details/D0A1PX
- Toxin and Toxin Target Database (T3DB)LICENSET3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.https://t3db.ca/downloadsFlurbiprofenhttp://www.t3db.ca/toxins/T3D2866
- California Office of Environmental Health Hazard Assessment (OEHHA)
- ChEBIChEBI Ontologyhttps://www.ebi.ac.uk/chebi/
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- California Safe Cosmetics Program (CSCP) Product Database
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licenceFLURBIPROFENhttps://platform.opentargets.org/drug/CHEMBL563Disease Classificationhttps://www.opentargets.org/
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- DailyMed
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFLURBIPROFENhttps://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/FLURBIPROFENNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- EU Clinical Trials Register
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/about-website/legal-notice
- FDA Liver Toxicity Knowledge Base (LTKB)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingflurbiprofenhttps://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/ltkb-benchmark-datasetFDA Liver Toxicity Knowledge Base (LTKB)https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb
- FDA Medication GuidesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawFlurbiprofenhttp://www.nist.gov/srd/nist1a.cfm
- SpectraBaseFlurbiprofenhttps://spectrabase.com/spectrum/IUz6Hu2c4SGSYTBZMRGLBWNTM-UHFFFAOYSA-Nhttps://spectrabase.com/spectrum/t3j6SWrPUyFlurbiprofen_neghttps://spectrabase.com/spectrum/JyJssiUSQ2yFlurbiprofenhttps://spectrabase.com/spectrum/8FcJR2Z1yrCFlurbiprofenhttps://spectrabase.com/spectrum/9I6wAjyoaxtFlurbiprofenhttps://spectrabase.com/spectrum/1gPKxASF6mRFlurbiprofenhttps://spectrabase.com/spectrum/8fgoSPKvLbj
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.kegDrugs listed in the Japanese Pharmacopoeiahttp://www.genome.jp/kegg-bin/get_htext?br08311.kegRisk category of Japanese OTC drugshttp://www.genome.jp/kegg-bin/get_htext?br08312.keg
- MassBank Europe
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlflurbiprofenhttps://rxnav.nlm.nih.gov/id/rxnorm/4502
- NMRShiftDB
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/ATC Classificationhttps://atcddd.fhi.no/atc_ddd_index/
- WHO ATCvet - Classification of Veterinary MedicinesLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://atcddd.fhi.no/copyright_disclaimer/ATCvet Classificationhttps://atcddd.fhi.no/atcvet/atcvet/
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policiesflurbiprofenhttps://www.pharmgkb.org/chemical/PA449683
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutflurbiprofenhttps://pharos.nih.gov/ligands/THH8FPRHHZR9
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidata(±)-flurbiprofenhttps://www.wikidata.org/wiki/Q419890
- WikipediaFlurbiprofenhttps://en.wikipedia.org/wiki/Flurbiprofen
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlFlurbiprofenhttps://id.nlm.nih.gov/mesh/M0008647.htmlAnti-Inflammatory Agents, Non-Steroidalhttps://id.nlm.nih.gov/mesh/M0001335.htmlCyclooxygenase Inhibitorshttps://id.nlm.nih.gov/mesh/M0025664.html
- PubChemPFAS and Fluorinated Compounds in PubChemhttps://gitlab.com/uniluxembourg/lcsb/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf
- GHS Classification (UNECE)GHS Classificationhttps://unece.org/about-ghs
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://maldi.nist.gov
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403381217https://pubchem.ncbi.nlm.nih.gov/substance/403381217
- NCBI
CONTENTS